Structure · schematic
Peptide chain of 11 amino acids · Sonstiges
Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid.
Research areas*
* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.
Mechanism of action
- ARA 290 (cibinetide) is a short peptide derived from helix B of erythropoietin (EPO).
- It binds to the so-called innate repair receptor (a complex of the EPO receptor and the β-common receptor subunit) without having the erythropoietic (blood-forming) action of EPO.
- Tissue-protective and inflammation-modulating effects have been described.
- The focus is on neuropathic and inflammatory conditions.
Research status
- ARA 290 has been investigated in early clinical studies, particularly in sarcoidosis-associated small-fibre neuropathy.
- Studies describe an improvement of neuropathic symptoms and an increase in corneal nerve fibres.
- The studies are mostly small and exploratory; there is no market approval.
- The substance has received orphan-drug status for certain indications.
Evidence level
Cited studies
Known risks
- 01Safety profile only from small, exploratory studies
- 02Injection-site reactions possible
- 03Long-term safety not established
- 04Product quality cannot be verified from unapproved sources
Frequently asked questions
What is ARA 290 (Cibinetid)?
ARA 290 (cibinetide) is a short peptide derived from helix B of erythropoietin (EPO).
What type of peptide is ARA 290 (Cibinetid)?
ARA 290 (Cibinetid) belongs to the Other class.
Is ARA 290 (Cibinetid) legal in Germany?
ARA 290 (Cibinetid) is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Where can I buy ARA 290 (Cibinetid)?
Peptica sells nothing and names no sources. ARA 290 (Cibinetid) is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
Is ARA 290 (Cibinetid) banned in sport (WADA)?
ARA 290 (Cibinetid) is currently not on the WADA Prohibited List.
What are the known risks of ARA 290 (Cibinetid)?
Documented risks include: Safety profile only from small, exploratory studies; Injection-site reactions possible. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is ARA 290 (Cibinetid)?
The evidence is classified as “early clinical studies”. 2 studies are cited on this page.
What is the molecular weight of ARA 290 (Cibinetid)?
ARA 290 (Cibinetid) has a molar mass of about 1257.3 Da.
Which peptides are related to ARA 290 (Cibinetid)?
Closely related entries: Erythropoetin (EPO). A direct side-by-side comparison is available via the compare function.
Related entries
Legal status
Germany
not approvedAustria
not approvedSwitzerland
not approvedEU
not approvedUSA
not approvedCanada
not approvedLegal status varies by country and can change. This is not legal advice.
Sources & methodology
- 2 peer-reviewed studies cited, linked to PubMed where available.
- Molecular data verified against PubChem and primary literature. PubChem CID 91810664
- Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.
Last editorially reviewed: 30 May 2026
Legal assessment
ARA 290 (cibinetide) is not approved as a medicine; it is in clinical development. As it has no erythropoietic action, it is not in the same category as EPO; it is not WADA-listed. Obtaining it as a research chemical carries quality and safety risks.
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.
Anzeige
Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.